Summit Therapeutics Inc Stock Performance
as on November 15, 2025 at 12:42 am IST
Day's Low
Day's High
$17.74$18.57
2.90%
Downside
1.64%
Upside
52 Week's Low
52 Week's High
$15.55$36.9114.89%
Downside
102.03%
Upside
Summit Therapeutics Inc share price movements today
- Previous Close
- $18.26
- Open
- $17.75
- Volume
- 785.8K
- Day's Low - High
- $17.74 - $18.57
- 52 Week Low - High
- $15.55 - $36.91
Summit Therapeutics Inc Historical Returns
- 1 Month Return
- -16.05 %
- 3 Month Return
- -30.96 %
- 1 Year Return
- -6.12 %
- 3 Year Return
- + 1639.05 %
- 5 Year Return
- + 276.49 %
Summit Therapeutics Inc Stock Fundamentals & Key Indicators
Check Summit Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$14.0B
EPS (TTM)
-0.8171
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
0.00%
PE Ratio (TTM)
-15.59
Industry PE ratio
8.355964912280701
PEG Ratio
0EBITDA
-935.0M
Revenue (TTM)
-
Profit Margin
0.00%
Return On Equity TTM
-292.49%
Summit Therapeutics Inc Stock Valuation
Track how Summit Therapeutics Inc P/E has moved over time to understand its valuation trends.
Summit Therapeutics Inc in the last 5 years
Lowest (-72.24x)
March 31, 2025
Today (-15.59x)
November 14, 2025
Industry (8.36x)
November 14, 2025
Highest (-0.61x)
April 30, 2023
Today’s Price to Earnings Ratio: -15.59x
Summit Therapeutics Inc vs Peer Comparison
Compare market cap, revenue, PE, and other key metrics of Summit Therapeutics Inc with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
|---|---|---|---|---|---|
| BUY | $14.0B | 276.49% | -15.59 | 0.00% | |
| BUY | $59.8B | 235.01% | 1414.81 | 1.36% | |
| NA | $40.9B | NA | 712.21 | 1.38% | |
| BUY | $110.2B | 92.67% | 30.58 | 31.35% | |
| BUY | $71.6B | 22.7% | 16.34 | 32.13% |
Stock Returns calculator for Summit Therapeutics Inc Stock including INR - Dollar returns
The Summit Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Summit Therapeutics Inc investment value today
Current value as on today
₹99,128
Returns
Returns from Summit Therapeutics Inc Stock
Dollar Returns*
₹5,194 (+5.19%)
Analyst Recommendation on Summit Therapeutics Inc Stock
Based on 7 analysts
85.71%
Buy
14.29%
Hold
0.00%
Sell
Based on 7 analysts, 85.71% of analysts recommend a 'BUY' rating for Summit Therapeutics Inc. Average target price of $31.77
Summit Therapeutics Inc Share Price Target
Get share price movements and forecasts by analysts on Summit Therapeutics Inc.
What analysts predicted
42.49%UPSIDE
Target Price
$31.77
Current Price
$18.27
Analyzed by
7 Analysts
Target
$31.77
Summit Therapeutics Inc target price $31.77, a slight upside of 42.49% compared to current price of $18.27. According to 7 analysts rating.
Summit Therapeutics Inc Stock’s Investor Sentiment and Interest
Investment in Summit Therapeutics Inc Shares on INDmoney has dropped by -19.91% over the past 30 days, indicating reduced transactional activity.
Time period: to
Search interest for Summit Therapeutics Inc Stock has increased by 42% in the last 30 days, reflecting an upward trend in search activity.
Time period: to
Change:42% versus previous 30 day period
Summit Therapeutics Inc Quarterly Profit & Loss
All numbers in Millions USD
Summit Therapeutics Inc Annual Profit & Loss
All numbers in Millions USD
Summit Therapeutics Inc Quarterly Cash Flow
All numbers in Millions USD
Summit Therapeutics Inc Annual Cash Flow
All numbers in Millions USD
Summit Therapeutics Inc News & Key Events
Today's Timeline - 20 October
Mon, 05:33 PM
-Summit Therapeutics reports Q3 2025 financials, highlighting significant net loss and increased operating expenses amid ongoing clinical trials.
Mon, 07:35 PM
-Summit announces plans for a Biologics License Application submission and new Phase 3 studies for ivonescimab.
Mon, 10:28 PM
-Summit reports higher R&D expenses in Q3 2025, exceeding analyst estimates, amid competitive trial results.
Today's Timeline - 20 October
Mon, 11:22 PM
-JMP Securities reiterates Market Outperform recommendation for Summit, with a price target increase reflecting positive outlook.
Tue, 00:22 AM
-Summit initiates Phase III study for colorectal cancer, reports positive trial results, and outlines future clinical expansions.
Insights on Summit Therapeutics Inc
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTBest in 3 Years
In the last 3 years, SMMT has outperformed top 5 stocks with highest market-cap in its industry
- POSITIVE IMPACT
Price Rise
In the last 3 years, SMMT stock has moved up by 1639.0%
NO EFFECTAgainst Peers
In the last 1 year, Beone Medicines Ltd has given 90.6% return, outperforming this stock by 96.7%
NEGATIVE IMPACTProfit Down
Netprofit is down for the last 5 quarters, -56.25M → -231.79M (in $), with an average decrease of 70.0% per quarter
- NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 3 quarters, 235.0K → -235.0K (in $), with an average decrease of 100.0% per quarter
About Summit Therapeutics Inc
| Organisation | Summit Therapeutics Inc |
| Headquarters | 601 Brickell Key Drive, Miami, FL, United States, 33131 |
| Industry | Health Technology |
| CEO | Mr. Robert W. Duggan |
| E-voting on shares | Click here to vote |
Key Management of Summit Therapeutics Inc
Name | Title |
|---|---|
Mr. Nathan LiaBraaten | Senior Director of Investor Relations |
Dr. Urte Gayko Ph.D. | Chief Regulatory, Quality & Pharmacovigilance Officer |
Dr. Allen S. Yang M.D., Ph.D. | Head of R&D Strategy |
Mr. Robert W. Duggan | Co-CEO & Executive Chairman |
Prof. Dame Kay Davies DBE, FRS CBE | Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor |
Mr. Bhaskar Anand | Chief Accounting Officer |
Mr. Dave Gancarz | Chief Business & Strategy Officer |
Dr. Fong Clow | Chief Biometrics Officer |
Dr. Mahkam Zanganeh D.D.S., M.B.A. | Co-CEO, President & Director |
Mr. Manmeet Singh Soni CPA | COO, CFO & Director |
FAQs
What is Summit Therapeutics Inc share price today?
Summit Therapeutics Inc share price today is $18.27 as on . Summit Therapeutics Inc share today touched a day high of $18.57 and a low of $17.74.
What is the 52 week high and 52 week low for Summit Therapeutics Inc share?
Summit Therapeutics Inc share touched a 52 week high of $36.91 on and a 52 week low of $15.55 on . Summit Therapeutics Inc stock price today i.e. is trending at $18.27,which is 50.50% down from its 52 week high and 17.49% up from its 52 week low.
What is Summit Therapeutics Inc's market capitalisation today?
Summit Therapeutics Inc market capitalisation is $0.01T as on .
How to invest in Summit Therapeutics Inc Stock (SMMT) from India?
- Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
- Step 2: Search for Summit Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Summit Therapeutics Inc Shares that will get you 0.0821 shares as per Summit Therapeutics Inc share price of $18.27 per share as on November 15, 2025 at 12:42 am IST.
What is the minimum amount required to buy Summit Therapeutics Inc Stock (SMMT) from India?
Indian investors can start investing in Summit Therapeutics Inc (SMMT) shares with as little as ₹88.7 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹887.00 in Summit Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ).
Based on Summit Therapeutics Inc share’s latest price of $18.27 as on November 15, 2025 at 12:42 am IST, you will get 0.5473 shares of Summit Therapeutics Inc. Learn more about
fractional shares .
What are the returns that Summit Therapeutics Inc has given to Indian investors in the last 5 years?
Summit Therapeutics Inc stock has given 276.49% share price returns and 19.94% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?